Domain > liberize-en-pbsinte.tevapharm.com

More information on this domain is in AlienVault OTX

Whois

Property	Value
Email	domainadmincorp@teva.co.il
NameServer	NS4.TEVAPHARM.COM
Created	1996-06-14 00:00:00
Changed	2015-04-01 00:00:00
Expires	2016-06-13 00:00:00
Registrar	DOMAIN THE NET TECHN

DNS Resolutions

Date	IP Address
2025-09-20	172.64.146.173 (ClassC)

HTTP/1.1 403 ForbiddenDate: Sat, 20 Sep 2025 21:50:03 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: closeaccept-ch: Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UAcf-mitigated: challengecritical-ch: Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UAcross-origin-embedder-policy: require-corpcross-origin-opener-policy: same-origincross-origin-resource-policy: same-originorigin-agent-cluster: ?1permissions-policy: accelerometer(),autoplay(),browsing-topics(),camera(),clipboard-read(),clipboard-write(),geolocation(),gyroscope(),hid(),interest-cohort(),magnetometer(),microphone(),payment(),publickey-credentials-get(),screen-wake-lock(),serial(),sync-xhr(),usb()referrer-policy: same-originserver-timing: chlray;desc982489452c5aff19x-content-type-options: nosniffx-frame-options: SAMEORIGINCache-Control: private, max-age0, no-store, no-cache, must-revalidate, post-check0, pre-check0Expires: Thu, 01 Jan 1970 00:00:01 GMTServer: cloudflareCF-RAY: 982489452c5aff19-PDXalt-svc: h3:443; ma86400

!DOCTYPE html>html langen-US>head>title>Just a moment.../title>meta http-equivContent-Type contenttext/html; charsetUTF-8>meta http-equivX-UA-Compatible contentIEEdge>meta namerobots contentnoindex,nofollow>meta nameviewport contentwidthdevice-width,initial-scale1>style>*{box-sizing:border-box;margin:0;padding:0}html{line-height:1.15;-webkit-text-size-adjust:100%;color:#313131;font-family:system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji}body{display:flex;flex-direction:column;height:100vh;min-height:100vh}.main-content{margin:8rem auto;padding-left:1.5rem;max-width:60rem}@media (width  720px){.main-content{margin-top:4rem}}.h2{line-height:2.25rem;font-size:1.5rem;font-weight:500}@media (width  720px){.h2{line-height:1.5rem;font-size:1.25rem}}#challenge-error-text{background-image:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIzMiIgaGVpZ2h0PSIzMiIgZmlsbD0ibm9uZSI+PHBhdGggZmlsbD0iI0IyMEYwMyIgZD0iTTE2IDNhMTMgMTMgMCAxIDAgMTMgMTNBMTMuMDE1IDEzLjAxNSAwIDAgMCAxNiAzbTAgMjRhMTEgMTEgMCAxIDEgMTEtMTEgMTEuMDEgMTEuMDEgMCAwIDEtMTEgMTEiLz48cGF0aCBmaWxsPSIjQjIwRjAzIiBkPSJNMTcuMDM4IDE4LjYxNUgxNC44N0wxNC41NjMgOS41aDIuNzgzem0tMS4wODQgMS40MjdxLjY2IDAgMS4wNTcuMzg4LjQwNy4zODkuNDA3Ljk5NCAwIC41OTYtLjQwNy45ODQtLjM5Ny4zOS0xLjA1Ny4zODktLjY1IDAtMS4wNTYtLjM4OS0uMzk4LS4zODktLjM5OC0uOTg0IDAtLjU5Ny4zOTgtLjk4NS40MDYtLjM5NyAxLjA1Ni0uMzk3Ii8+PC9zdmc+);background-repeat:no-repeat;background-size:contain;padding-left:34px}@media (prefers-color-scheme: dark){body{background-color:#222;color:#d9d9d9}}/style>meta http-equivrefresh content360>/head>body>div classmain-wrapper rolemain>div classmain-content>noscript>div classh2>span idchallenge-error-text>Enable JavaScript and cookies to continue/span>/div>/noscript>/div>/div>script>(function(){window._cf_chl_opt  {cvId: 3,cZone: liberize-en-pbsinte.tevapharm.com,cType: managed,cRay: 982489452c5aff19,cH: _PUOqKomtAVaBl9FjUVu7Ss2OykiTDqfugRpdR4GB4k-1758405003-1.2.1.1-juELudP_kgAi9u5MI0tulMViUlerFbFgVa4CEkXp1FBlkSDEqMACBc0madPyI0b5,cUPMDTk:\/?__cf_chl_tkOTNK1WFXg_L5IAoGtgOax0LL4czUDACCneRN6rxUzzw-1758405003-1.0.1.1-hnc_OUrwA.9xu6KGrdj6N.K9l.Yvm60Raej.QXOLguk,cFPWv: g,cITimeS: 1758405003,cTplC:0,cTplV:5,cTplB: cf,fa:\/?__cf_chl_f_tkOTNK1WFXg_L5IAoGtgOax0LL4czUDACCneRN6rxUzzw-1758405003-1.0.1.1-hnc_OUrwA.9xu6KGrdj6N.K9l.Yvm60Raej.QXOLguk,md: Q.3wq3WiWwYnSc2ocyTp1nLcX8fmEohxPe8qwG8aFv0-1758405003-1.2.1.1-fHrUJtkAfhEtPKjwl_WAU.Geqb5WLLTBxfuKEsyUl_P7cTNBgCtYhizOXJeXSvN_1RloGCI_RwRvuysGJ_F10jXDJgtA12JR57n28TWGtYEDd92RcYGeiK51rGbi7uhkPiJSVXTbjS1I8KnZUB_Ird3aOXWRyhzxOmMDGhy5XSQiw7bxM63FH446jir9TNGLe8ilnKR9Zun8VgtVywC2TPSvLQqtZ2jEZ0OVsaLzHwVcqBHzkf00m5Rp6CsTTYcBxfsypKULRxBggAq5vAEkZHdilAqV.Cr_UJ97WeDCsDbGRF09V5fdJmrGz86lf6NiiXfznIi9XI2LO2jRi30tOZzuAxx6C4u4UVOay1TQLRvy4EQg0qnsdn_OOJr61UdwOA9y7MAuEx0WhNDWJVWo806wvDWWqaxWd9rsGTECxOI0HRpDQXhaMj_RwemSFgrU1iKt05oDmYGW35EwqihVcItAOi1PJFg7jQutK.3yGNmPlCoZahN9R_wx5eQvF_KJoQenveZYyHHMdccHZ7PKSgpiH9J8ZFIpBpb79EMEvP7VHdGmuFNcfKkxvUIhzLLFwZo4p1eV.z_izU.Muonpy0e1XPOsD4re0fU4C.Kusg8vkemmGH0U8bQ_1G5LlJ6Vd9f_9lX0UmmYbxP4n_ddFjLnQO56FcOaKS8Uv_3z7JqQJNsKOmkTSbIADyrnjaHIXcPR2U4kOoSaoWL_ns1GZTjs7UJLrCUMV3aVH.qZQsqflN5zYy8u7u9wpQBTFtoUQwSPml5PWU8V8P21lRJAjSNz88Fp_WPw4jWce.42JDYXzStHlOB2eLhM4wEWGrtJD.HuxOXDIHHD8C4WOHrqSSI6DY1AM6aB_hNu1EaMM_AqNQfU6twl8alQyRVIeNYliVJL5Pt1i93O5tC206XQI6lRjOL2Hw8jeWVmO0CTz5mfUd4RVWTKsCPBqYZKFQb3,mdrd: nWdhZcdPKh4zRCXzjfafkhK4MGraYk4FXFngT8HfB0g-1758405003-1.2.1.1-MixLz9mUfedGG68mxXRpflRTMcASdXf3Xw7NBpfdZ8BOR068V5IfW9_SWoCzuwZTt8UujtM6sG6Qr7sEcGO9ed4pMWBdItknwuJ47U.V27stjLlGCID1armoa4vRz8VRXe_AcZ3fyz1RBW7ToGfr8wi082zaWVmv_41AfU_RtBxjUHAkUBoNOCAIk7r18sKd3fdcH9jYmz_fTfbAWOagGc4Kol1MOSWjbTsv5Tkjx69QzyhpW9_HNuEKEEx024djISIryb4rp6K18W.WMCnJ01zMRXUJ1b_xN.LJ4ZyXMkhjzwkzUt.GXcxFZNxF1x.JHCFUguAgoamEw6KnqMsChUkfjdYFVQJrj2ZJviJHxSugKipONkHIErgZPJOxU9XwNbR_XfqXtnSMmo6l6ZzQh3kIzqXtSuIC35UZEFaJNB8q75YL_oxB9.igelBUKC3zN5C3u9mLTRH_8O1IyIXUNc823g55CDjxAkVA6.pgFh3aj8dq3oFTiw9RZ5vMFvkECOrOY8H5JkdpsdcdjhuKr4Szqe40IYb3akoxs48kC4Bo9hWA5Th2meFLlnhqRdRy,};var a  document.createElement(script);a.src  /cdn-cgi/challenge-platform/h/g/orchestrate/chl_page/v1?ray982489452c5aff19;window._cf_chl_opt.cOgUHash  location.hash   && location.href.indexOf(#) ! -1 ? # : location.hash;window._cf_chl_opt.cOgUQuery  location.search   && location.href.slice(0, location.href.length - window._cf_chl_opt.cOgUHash.length).indexOf(?) ! -1 ? ? : location.search;if (window.history && window.history.replaceState) {var ogU  location.pathname + window._cf_chl_opt.cOgUQuery + window._cf_chl_opt.cOgUHash;history.replaceState(null, null,\/?__cf_chl_rt_tkOTNK1WFXg_L5IAoGtgOax0LL4czUDACCneRN6rxUzzw-1758405003-1.0.1.1-hnc_OUrwA.9xu6KGrdj6N.K9l.Yvm60Raej.QXOLguk+ window._cf_chl_opt.cOgUHash);a.onload  function() {history.replaceState(null, null, ogU);}}document.getElementsByTagName(head)0.appendChild(a);}());/script>/body>/html>

Port 443

HTTP/1.1 403 ForbiddenDate: Sat, 20 Sep 2025 21:50:03 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: closeaccept-ch: Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UAcf-mitigated: challengecritical-ch: Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UAcross-origin-embedder-policy: require-corpcross-origin-opener-policy: same-origincross-origin-resource-policy: same-originorigin-agent-cluster: ?1permissions-policy: accelerometer(),autoplay(),browsing-topics(),camera(),clipboard-read(),clipboard-write(),geolocation(),gyroscope(),hid(),interest-cohort(),magnetometer(),microphone(),payment(),publickey-credentials-get(),screen-wake-lock(),serial(),sync-xhr(),usb()referrer-policy: same-originserver-timing: chlray;desc98248945efc9ff15x-content-type-options: nosniffx-frame-options: SAMEORIGINCache-Control: private, max-age0, no-store, no-cache, must-revalidate, post-check0, pre-check0Expires: Thu, 01 Jan 1970 00:00:01 GMTServer: cloudflareCF-RAY: 98248945efc9ff15-PDXalt-svc: h3:443; ma86400

!DOCTYPE html>html langen-US>head>title>Just a moment.../title>meta http-equivContent-Type contenttext/html; charsetUTF-8>meta http-equivX-UA-Compatible contentIEEdge>meta namerobots contentnoindex,nofollow>meta nameviewport contentwidthdevice-width,initial-scale1>style>*{box-sizing:border-box;margin:0;padding:0}html{line-height:1.15;-webkit-text-size-adjust:100%;color:#313131;font-family:system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji}body{display:flex;flex-direction:column;height:100vh;min-height:100vh}.main-content{margin:8rem auto;padding-left:1.5rem;max-width:60rem}@media (width  720px){.main-content{margin-top:4rem}}.h2{line-height:2.25rem;font-size:1.5rem;font-weight:500}@media (width  720px){.h2{line-height:1.5rem;font-size:1.25rem}}#challenge-error-text{background-image:url(data:image/svg+xml;base64,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);background-repeat:no-repeat;background-size:contain;padding-left:34px}@media (prefers-color-scheme: dark){body{background-color:#222;color:#d9d9d9}}/style>meta http-equivrefresh content360>/head>body>div classmain-wrapper rolemain>div classmain-content>noscript>div classh2>span idchallenge-error-text>Enable JavaScript and cookies to continue/span>/div>/noscript>/div>/div>script>(function(){window._cf_chl_opt  {cvId: 3,cZone: liberize-en-pbsinte.tevapharm.com,cType: managed,cRay: 98248945efc9ff15,cH: jdoArG2hYZHqc9P9BiWpNFJ8eacycRuRiA2u.yWHvGQ-1758405003-1.2.1.1-oxM6EEKt9BxfTt8q7QAGwOhUMORDYguVQVF92B82DjMP7.1_Yce9BtETRe3bvgPm,cUPMDTk:\/?__cf_chl_tkO6BZLtzAQUXXfloXShSBQUmN3IKHKhczPEsumNHiE4k-1758405003-1.0.1.1-LtLVLAoke53nPZ1W4LfnYBplp.ekfz8sQCzuzKfDub0,cFPWv: g,cITimeS: 1758405003,cTplC:0,cTplV:5,cTplB: cf,fa:\/?__cf_chl_f_tkO6BZLtzAQUXXfloXShSBQUmN3IKHKhczPEsumNHiE4k-1758405003-1.0.1.1-LtLVLAoke53nPZ1W4LfnYBplp.ekfz8sQCzuzKfDub0,md: 8rPz1_U75qtcOaSk3VPyy4jGUCK7JfGru9d6qpiFH08-1758405003-1.2.1.1-KS1cWY8O9IWfX2sNmZHdBWEgRC3jLHsWkG5Bhbhgpsa6vQBrP5GA35jxk8vYvZ5xGd0HB0cqKsScGvJbDQkQMgUJoJrxXpHe37ZWElz1T8XPxVwUdcb.aeX92Axh75Jakn7oSxyaLrtcsaZDocHgBW.xSW47.wumaWmJ6dZ8w462QDrCf8hjq53z2d5wAxu3cwECxczGZbXJHEipEzfzQwfoiIuGIYQjguA4o56iDXVR0M0mrv8lG3ARzVTaIyRBxMIyNqdMUnWOxE_meKezLSCrbxXMDe1rpRxG8a5UQ0tJ2Dy07mH20mMFZMEBFHDKuPjXz95n1rmrECy2gFsQyK7p.Wbkgrpum69.hA.XUMFo5zyXoFr_UJp5qOBZfxNeMLr5xVMwvTZcYh1pHcAK4hOGu7.s6ztRzi9iHG8ZG2CJK7q4WQKNMt2W476M8LX6jVxQkxmrDKjDCggSgAtAz7POkmOKk.3uyg_fkRikmaOnDBZ9telRsKc_G6UJ0MjDoIMYL8WK6RMydwnFs8C.N3mom6lrW2H2sS4WnN.F_iKQOpbQUxvPl0zIfZQ.Sihn0QuOUR_8erdaH.oH8QLsN_04aUgAEng.uoT5ub1.lCtCvD7B4ef1RRHyTafB1ql9t8Vg.VXQbr3bXWd0fEfTw74w57sLDST6_uKjIvXEFuTl6ErthiHDBlA_A61japL42qKoQAgOsj8Snf86BhZoz4FOSMzzUl.yyCaMVRjFrJUegR0LM1f_AVeCOqkVGwo_VSVZn1luah1zsPITGtW2YbtKHWuysLGojGs9Yg2aOytoeCTvV.UIuOOmWpIyK565EB7BPwSexBspx3AnsYbbufdSnZyEG5owOTx4_PMlni71DGCpAy9RI9LLPDiyAQnq7kVIGNcy0e04ysIBvQxx94mLJLZFCPXMLmk.zSoUfn12yjPifOKiMdhZVji9c9dn,mdrd: eTXjujanUxqvSwrgWT5Jx0uMCyqPGeli1sO8sx.3zfM-1758405003-1.2.1.1-r4Lhw2lSDtlxMm1dVFhL.5F8xsPQNG8QluOy4nXcAAEPeXakMW1OqP037loVU6B1O12U8ez0liC1K3h0ksaG7Ki1cEaDxUSakOOK9Djf8iAx3Shly0WfB2pGiT6JzlMWkVEk969cmfcH7p7OkXugokj4WNfUnxoq_Wg9OE3UOa13WXE5XdC5UElcyI8Jye.86cMBVYmu1Hlfgb_o4bN9_vk2_wtRAG.kVSkF5n4nPQBhpDFxMRW1Lt8wsTLJEALldhXtzDyq._33_tmwMa.bc9tHXKbFtm.2nltlrwbRW3fq54z9GqK9aIo3Lqv8y5eQ73FwWrhKk1GVpJHKghSzHbke2wfGEDDwG2MaTWNTwtWFOiTebUFRrkvsh46dyixQ3nTcp8zKsQ0uYSR9mu_uCdMywPNfrD2kWxN0BhmfyFcI7Wxoh387V8UdSlRipr.fQx1AymTW0W_pA2jwuzMYw9serj2eiEQu_K.Cvh_xxt8m48zq8XW8T8RPil_nsALaHRHEsPVA401lS5sQJnU2pxrwiFfkYKmBnPHAjMUr5ur8_JIV3Cv93htobaTRWSsFOkz2z3WN3kfUeMDLOXFkG2yKZm6IBBY485vUIm7nLK6LGLvWh4v5mCjvlsuv_7k0pfV4HHFNT9yEfjo.14OWEvsxkNFqMTay8JZZMaEaCcmcYRiGwcCvIqYkkG1LkekkHa_1f4c2sLG_JrxlbV_S_usIjTuC.9k4kUt2QRnXojImxJ1m7JhtLvvv.bFBV9xRssAo1YhPqXNR_f0N1.KXlpL3tDWG0m8ru4SvrpwE6IAECCegLL4fepawi9EI5fKH83kgDXLy5iCdv7Ff8lY3TNiGEGnP3844AW26G4YlkqU.ASCtC2xF_NqKzXzwXaCUG22nUCqVJhf_h09.ccNPf8zAXGka4O981wjYu4iTTgFiaRu_upc7IYF45trEwt5ZQomNr7iGOTqj5T_kwdCz3fgDdoarRoF82IJr9sMOA3a9M7ZSpDGtaKorLlEyudOkTPGumr9Mej2z_5XYT9Q6bHx0IofPfcCw5RTq2w0WUuiV8izZOlLsckQQfCbBHBF8EgM7WXPELekY671PHtpZjRYp11mBPSDuYwcASEqHYyp4dPSi0cyHjmG0ZlMrvA8RzG07l2otgzXfctqO2WsOtN7nkCA.UZL9aaDttWvp.N88i34N1zKDmswP1YHUsZthnvgIZNzG9UciAw3dbH_nteX7nTFUhQLWk7rmrZO2x1pEfyogSIN753ql.jfWm6hnUhovoqtzMFjJz.ordN_nrofQ2T1xegaBoYtkyo08e9BHk1z3DztzIR_LJWeHfUCXmOXtXzbdiOux0kitCi8nO0uMuXeBIvTWFePPez8Tmww4BT6H2AOkhINyTG1VhfOYzEfCzvQgHO2Bvfh.Ltxlc6iEPKEIPIRzm2mF3lC.czWiIKMrt8dZVAfDUN.rXkH4KeGGorBEto3kYNYTSgyb703Zs3rM44NrH4oRHgNA3ysP.BNzRbNNc5vOd_XBFExH.vlxcayJBAQ21oGWcmNXlqD8nSWRXpzT8yDYM_LBYtizARUO9LN5gTPcnr2pp4frA.WzWMQXUCHYlqP_8F._dvQze0lQzpyEqxZ07I9nKI67UfBkQgppK2YYPGvTl.GTG7yO0kazgGQ98RLh3bhyiJQ5IF_VumeDPheHDROm8YBGoXYHeB5k97mzZrGz2kTIClopu6mLItWFCzNIP0roIqxUMWvzq3rdJ.xcACqmQBTTgZ61CYDjF..yjqQ2FuGPVj_WvGRmPqgGS2hDyDr6DNGZGusCArSwSjgjg67ZAeHMc.Cbqu_nych7CtLqmIQ_ejEgHtzncGKNcnOPeXgLa8ITOE6WoCAca1cnkSJ.BksagLkbM9p2Syr4AzwIND2j7S9kl_9v75K_YlLbWdeCgA,};var a  document.createElement(script);a.src  /cdn-cgi/challenge-platform/h/g/orchestrate/chl_page/v1?ray98248945efc9ff15;window._cf_chl_opt.cOgUHash  location.hash   && location.href.indexOf(#) ! -1 ? # : location.hash;window._cf_chl_opt.cOgUQuery  location.search   && location.href.slice(0, location.href.length - window._cf_chl_opt.cOgUHash.length).indexOf(?) ! -1 ? ? : location.search;if (window.history && window.history.replaceState) {var ogU  location.pathname + window._cf_chl_opt.cOgUQuery + window._cf_chl_opt.cOgUHash;history.replaceState(null, null,\/?__cf_chl_rt_tkO6BZLtzAQUXXfloXShSBQUmN3IKHKhczPEsumNHiE4k-1758405003-1.0.1.1-LtLVLAoke53nPZ1W4LfnYBplp.ekfz8sQCzuzKfDub0+ window._cf_chl_opt.cOgUHash);a.onload  function() {history.replaceState(null, null, ogU);}}document.getElementsByTagName(head)0.appendChild(a);}());/script>/body>/html>

Subdomains

Date	Domain	IP
tws01.tevapharm.com	2025-07-22	45.60.152.158
mx01.tevapharm.com	2013-05-16	192.115.248.100
eudigital02.tevapharm.com	2025-07-03	45.60.122.67
mx02.tevapharm.com	2014-04-25	192.115.251.27
ns3.tevapharm.com	2025-09-08	199.7.68.228
ns4.tevapharm.com	2025-09-19	199.7.69.228
ns5.tevapharm.com	2025-06-21	204.74.114.228
sfc.tevapharm.com	2025-09-09	45.60.151.76
us.sfc.tevapharm.com	2025-06-28	45.60.152.158
eu.sfc.tevapharm.com	2025-07-16	45.60.152.158
genuse.tevapharm.com	2025-07-01	45.60.152.158
www.genuse.tevapharm.com	2025-07-08	45.223.137.231
aktivmitms-ch-de-pbsinte.tevapharm.com	2025-06-30	172.64.146.173
ajovyde-pbsinte.tevapharm.com	2025-06-19	104.18.41.83
digihaler-uk-pbsinte.tevapharm.com	2025-09-20	172.64.146.173
ajovy-uk-pbsinte.tevapharm.com	2025-07-02	172.64.146.173
ajovy-il-pbsinte.tevapharm.com	2025-06-19	172.64.146.173
aviomarin-pl-pbsinte.tevapharm.com	2025-07-01	172.64.146.173
ajovyca-en-pbsinte.tevapharm.com	2025-06-20	172.64.146.173
liberize-en-pbsinte.tevapharm.com	2025-09-20	172.64.146.173
alvaiz-en-pbsinte.tevapharm.com	2025-05-24	172.64.146.173
ajovy-ca-fr-pbsinte.tevapharm.com	2025-05-23	104.18.41.83
aktivmitms-ch-fr-pbsinte.tevapharm.com	2025-05-25	104.18.41.83
ajovygr-pbsinte.tevapharm.com	2025-06-22	172.64.146.173
ajovy-ir-pbsinte.tevapharm.com	2025-05-21	104.18.41.83
kopf-klar-at-pbsinte.tevapharm.com	2025-09-01	172.64.146.173
selfcare-it-pbsinte.tevapharm.com	2025-09-20	104.18.41.83
tws01-dev-onboarding.tevapharm.com	2025-05-21	45.223.137.231
tws01-dev-catalog.tevapharm.com	2025-07-14	45.223.137.231
general.tevapharm.com	2024-04-20	13.107.213.70
copaxone-de-pbsprep.tevapharm.com	2025-09-20	172.64.146.173
aktivmitms-ch-de-pbsprep.tevapharm.com	2025-06-22	172.64.146.173
ajovy-uk-pbsprep.tevapharm.com	2025-08-12	172.64.146.173
ajovy-il-pbsprep.tevapharm.com	2025-07-02	104.18.41.83
aviomarin-pl-pbsprep.tevapharm.com	2025-05-26	104.18.41.83
ajovyca-en-pbsprep.tevapharm.com	2025-05-26	104.18.41.83
teriparatide-en-pbsprep.tevapharm.com	2025-09-20	172.64.146.173
alvaiz-en-pbsprep.tevapharm.com	2025-05-26	172.64.146.173
aktivmitms-ch-fr-pbsprep.tevapharm.com	2025-05-26	104.18.41.83
ajovygr-pbsprep.tevapharm.com	2025-06-24	172.64.146.173
ajovy-ir-pbsprep.tevapharm.com	2025-06-01	104.18.41.83
wti-clinical-trials-es-pbsprep.tevapharm.com	2025-09-19	104.18.41.83
tws01-pp.tevapharm.com	2025-06-21	45.223.137.231
ir.tevapharm.com	2014-04-16	165.254.206.89
hcpportals.tevapharm.com	2025-07-09	45.60.122.67
status.tevapharm.com	2025-08-19	13.69.68.44
tws01-dev-content.tevapharm.com	2025-07-02	45.223.137.231
qa1.tws01-dev-content.tevapharm.com	2025-07-24	45.223.137.231
tws01-int.tevapharm.com	2025-08-26	45.223.137.231
www.tevapharm.com	2024-11-25	45.60.151.76

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > liberize-en-pbsinte.tevapharm.com

Is this malicious?

Whois

DNS Resolutions

Port 80

Port 443

Subdomains